Date Title Document
Date 06/09/26 Title Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of PrOKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia Document pdf
Date 06/09/26 Title Bausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDIMC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophrénie Document pdf
Date 05/28/26 Title Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China Document pdf
Date 05/19/26 Title Bausch Health Announces 2026 Annual Meeting of Shareholder Results Document pdf
Date 05/13/26 Title Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference Document pdf
Date 05/12/26 Title Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference Document pdf
Date 04/29/26 Title Bausch Health Announces First Quarter 2026 Results Document pdf
Date 04/14/26 Title Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering Document pdf
Date 03/31/26 Title Bausch Health to Announce First Quarter 2026 Results on April 29, 2026 Document pdf
Date 03/26/26 Title Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program Document pdf
Date 02/23/26 Title Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + BrilliantMD Touch Laser in Canada (French) Document pdf
Date 02/23/26 Title Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada Document pdf
Date 02/19/26 Title Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres Document pdf
Date 02/18/26 Title Bausch Health Announces Fourth Quarter and Full-Year 2025 Results Document pdf
Date 02/17/26 Title Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference Document pdf
Date 02/11/26 Title Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Document pdf
Date 01/23/26 Title Bausch Health Provides Update on RED-C Phase 3 Clinical Trials Document pdf
Date 01/21/26 Title Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026 Document pdf
Date 01/05/26 Title Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference Document pdf